Scancell Share Discussion Threads

[2tyke] 18/7/2023 10:32

Small crow:
As he has already declared...in advance ...Mr tyke has already mopped up the bulk of the bulls stock. And it is in profit already as EW expected.
Meanwhile you will be constantly confused by the unfolding pattern....so best you disappear !! Lol

[chillpill] 18/7/2023 10:25

Agree MT. Seems a really badly executed sell order. In addition to the options I think Sir Martin Wood’s stake is the most likely.

[chilltime] 18/7/2023 10:07

Adding to that.

After a long stint (days) peel have just (10.53) left the offer going onto the bid, which may explain the move and now apparent more normal market.

[chilltime] 18/7/2023 10:01

Trading weakness large sells.

A few days ago in the midst of the dive regular reports surfaced EG around 11 x 250k sells.

Dips spook PIs who assisted the drop.

Goodfellow had 2.88m in options to execute at 4.5p and probably did post the news update, cashing in hence the largish sells.

Trades aren't necessarily all sells as reporting can mean, the number into the market then back out, 2 reports,

Yesterday two sells close together came to about 500k then a 300k later.

Peel Hunt have been the dominant one on the offer throughout, suggesting they are/were the ones with the stock.


On top of that during or prior there is Seneca Capital. They hold Scancell and declared a 2p dividend for the relevant fund of which there re only two shares 75% of which are Scancell.

In their AGM presentation (May 23) they stated they were selling Scancell to pay the 2p dividend.

They did that last year too 1m at over 20p, so this year the likely sell requirement would be around 1.5m-2m shares, tp fund the dividend. They treat Scancell as their dividend cash each year.

So add Goodfellow to Seneca and that's probably 4.5m or so shares sold from larger holdings, hence the recent weakness.

[tosh123] 18/7/2023 09:25

No one needs to trawl ineptico.... there are numerous posts from you arguing about the transfer of mouse data to humans, loads of them ! !
You argued and argued that the results would be directly replicated.
I recall having many arguments about that very topic, and also suggested that you speak with Lindy as she ( along with the rest of the educated world ) would not be able to guess the results.

I also remember Bermuda telling you exactly the same, but as usual, you didn't listen and as such have ONCE AGAIN, made a massive error in judgement and been proven to have been wrong... yet again !

Don't you get tired of being proven wrong ???
Why not just accept that you have made mistakes ?

[wigwammer] 18/7/2023 09:25

Thanks inanaco.. I see that.. but why not just say it in the RNS? If it is still 8 on the trial - great. If it is 2 - then that's open and honest.

[marcusl2] 18/7/2023 08:57

new 6-month evaluation by a leading Biotech company.

[marcusl2] 18/7/2023 08:57

A data package has been generated for the Glymabs for Car T so also expect a Car T deal.



(remember this is only Modi-1, no CPI. It is looking like Fulldose Modi-1 PLUS check point inhibitor will work best)

In the other monotherapy cancer cohorts, a total of eight patients have received full dose Modi-1

-- One TNBC patient remains on trial with stable disease beyond 8 weeks
-- One head and neck patient achieved a partial response and remains on study at week 37

Dr David Pinato, Principal Investigator at Imperial College, commented: "Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in patients who have exhausted most treatment options is very encouraging".

[inanaco] 18/7/2023 08:56

Go and have a Trawl Gerald ...

[inanaco] 18/7/2023 08:49

wig cant go in to specifics like that, it would be a big no no and Lindy would not reply

Sorry

[marcusl2] 18/7/2023 08:41

As usual I got my timing wrong piling in at 11p !

[marcusl2] 18/7/2023 08:37

This will recover. The results so far are good and very early days.

Hopefully we can get permission for a CPI with Ovarian.

Only 3 patients have been recruited for full dose Modi-1 + CPI.

Scib plus doublet looking excellent, change to iScib+ soon.

I expect deals for A glymab and Avidimab.

I also think Immunobody and Modi-1 will get licensed at phase II.

Lindy always said that they would use biomarkers to determine who is likely to benefit.

[chillpill] 18/7/2023 08:20

One school of thought is it could be the Estate of Sir Martin Wood selling his shares. He and his wife both had a total of around 8m shares. Unverified though.

[small crow] 18/7/2023 07:57

Obviously Mr Tyke will be buying now. Then, as quick as he "arrived`' he will be gone....

[panama7] 18/7/2023 07:53

Inanaco, I hope you are not trying to rewrite History, haven't you been telling everyone for 10 years that you can find no mechanism of failure. Didn't you for 10 years tell everyone that Modi was a stand alone platform. Unlike you other posters do not trawl through years of posts to prove a point but it is all there in your history. Anyway some good news for Scancell there are going to be a hell of a lot more cancer patients in the next couple of years SV40.

[wigwammer] 18/7/2023 07:42

Hi inanaco.. has Lindy mentioned how many of the reported 8 non-ovarian patients are still taking moditope? Would be good to get some clarity on that

[inanaco] 18/7/2023 07:27

by the way i have discussed this with Lindy ... i am not posting blind unlike some

[2tyke] 18/7/2023 07:25

I think you'll need to look much further than CD4 T cells inane.
Because the stock price was plummeting when everyone thought they were working !
Lol

[inanaco] 18/7/2023 07:21

Lindy is not going into this cold ..... because the data sets from existing Ovarian cancer trials can be looked at ... and hopefully samples from moditope patients with ovarian may be available

Data has Value ... i mentioned this before even trials that have failed

[inanaco] 18/7/2023 07:13

anyway your chosen Expert Bermuda has already Bailed ... unable to comprehend the TME
Ruck ...

so if your out looking in ... you have motive

Crumbs is in, looking out ... and is probably very sensitive to the financials which is understandable .. however moaning won't help him, he has to understand why or what is holding back those CD4 T cells ... because they are there

and the Best person to solve this is Lindy, who has overcome every technical hurdle presented so far

[inanaco] 18/7/2023 07:06

Ruck don't beat yourself up again over your paper loss or try and pass the buck ........ you bought the shares

own it

Kicking me won't help you at all ........ Avatar's don't feel pain

[inanaco] 18/7/2023 07:02

Ruckrover .. in relation to SCIB1 ... no i could not

in relation to Modi1 ... its worked

ATB

[inanaco] 18/7/2023 07:00

we took on Ovarian because it's hard .......... its an monopoly market if we can make it work

OC - Ovarian


Despite strong biological rationale, epithelial OC has not proved to be the ideal candidate for ICIs. Resoundingly negative clinical data from phase I, II and III trials confirm the lack of benefit for single agent PD-L1/PD1 inhibition in PROC. Whether this rules out all immune-modulatory strategies in PROC remains to be determined. Typically ‘immune cold’ OC may require combinatorial approaches to improve benefit. Preclinical and early phase clinical studies support combining PD-L1 inhibition with conventional cytotoxics, PARPis or anti-angiogenics. A huge number of patients are being treated within ongoing phase III randomized trials evaluating the benefit of ICI +/− PARPi +/− anti-angiogenic in first line. These studies are enrolling all comers, with some exceptions, often stratified on BRCA1/2 status and PD-L1 expression. The questions will be regarding tolerance, magnitude of benefit in the whole population, in defined subsets, cost, and the true value of putting all our molecules in frontline, leaving relapsed disease an area of unmet medical need. The PD1/PD-L1 axis may not be the most relevant immune checkpoint in OC. There is a huge number of other actionable immune co-regulatory molecules (IDO, LAG3, TIGIT, OX40, TIM3, NKG2A, CD47, Sirp1α, etc....) and many can already be targeted by drugs in early development. It will be crucial to gain more insight into the unique molecular and immune features of the ovarian TME in order to optimize benefit from ICIs for patients with OC.


at some point all these trials may come up with a support strategy to help Cd8 T cells

but none of them have access to CD4 Killer t cells which have worked !!!! without assistance

if we can crack this we open the moditope Pandora's box

[ruckrover] 18/7/2023 07:00

Inan, "I appreciate the mouse model has not transferred like the immunobody mouse,"Wasn't it on the very question of whether mouse data would be replicated in humans that you said "I can find no mechanism of failure"?